Mentions in press and media 1
| Date | Title | Description |
| 08.12.2021 | Lumira Co-Leads OncoMyx $50 Million Series B to Advance a Novel Immuno-Oncology Platform that Delivers Multiple Cancer-Killing Payloads | OncoMyx Therapeutics, a privately-held immuno-oncology platform company, today announced the closing of a $50 million Series B financing, co-led by Lumira Ventures and B Capital Group with participation from LYZZ Capital and all Series A in... |